Surgery
Volume 133, Issue 1 , Pages 24-31 , January 2003

Treatment response and prognosis of patients after recurrence of esophageal cancer

,Accepted 19 June 2002.

References 

  1. Isono K, Onoda S, Ishikawa T, Sato H, Nakayama K. Studies on the causes of deaths from esophageal carcinoma. Cancer. 1982;49:2173–2179
  2. Isono K, Ochiai T, Okuyama K, Onoda S. The treatment of lymph node metastasis esophageal cancer by extensive lymphadenectomy. Jpn J Surg. 1990;20:151–157
  3. Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T, Okudaira Y. Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet. 1983;157:537–540
  4. Raoul JL, Le Prise E, Meunier B, Julienne V, Etienne PL, Gosselin M, et al.  Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut. 1995;37:174–176
  5. Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg. 1996;182:340–346
  6. Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–1433
  7. Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S, et al.  Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;2:275–281
  8. Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for implications. Br J Surg. 1996;83:107–111
  9. Ribeiro U, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, et al.  p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998;83:7–18
  10. Nasierowska-Guttmejier A, Szawlowski A, Jastrzebska M, Jeziorski K, Radziszewski J. p53 protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma—preliminary report. Dis Esophagus. 1999;12:128–131
  11. Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol. 1999;12:251–256
  12. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VMG, Bennett WP, Liang L, et al.  Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res. 1996;56:4917–4921
  13. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous cell carcinoma in India. Int J Cancer. 2000;85:791–795
  14. Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al.  Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today. 2001;31:591–596
  15. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23:263–266
  16. Maccio A, La P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlation with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69:248–252
  17. In: 5th ed.  Sobin LH,  Wittekind CH editor. UICC TNM classification of malignant tumor. New York: John Wiley and Sons, Inc; 1997;
  18. The Japanese Society for Esophageal Diseases. Comprehensive registry of esophageal cancer in Japan (1988-1994). 1st ed.
  19. Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H, et al.  Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg. 1994;219:310–316
  20. Bedard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 2001;91:2423–2430
  21. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562–572
  22. Kelsen D. Treatment of advanced esophageal cancer. Cancer. 1982;50:2576–2581
  23. Fahn HJ, Wang LS, Huang BS, Huang MH, Chien KY. Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus. Ann Thorac Surg. 1994;57:677–681
  24. Harpole DH, Moore MB, Herndon JE, Aloia T, D'Amico TA, Sporn T, et al.  The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7:562–569
  25. De Mello J, Struthers L, Turner R, et al.  Multivariate analysis as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer. 1983;17:251–255
  26. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201
  27. Shimada H, Okazumi S, Matsubara H, Miyazawa Y, Arima M, Funami Y, et al.  Serum p53 antibody is a useful tumor marker in the patients with superficial esophageal cancer. Cancer. 2000;89:1677–1683

☆ Supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan (Advanced Medicine Development Project and #12671200).

☆☆ Reprint requests: Hideaki Shimada, MD, Department of Academic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8677, Japan.

★ 0039-6060/2003/$30.00 + 0

PII: S0039-6060(02)21637-2

doi: 10.1067/msy.2003.31

Surgery
Volume 133, Issue 1 , Pages 24-31 , January 2003

Article Tools

* Image Usage & Resolution